. Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am J Physiol Heart Circ Physiol 286: H1146-H1153, 2004. First published November 20, 2003 10.1152/ajpheart.00720.2003.-We recently developed a mouse model with a single functional allele of Serca2 (Serca2ϩ/Ϫ) that shows impaired cardiac contractility and relaxation without overt heart disease. The goal of this study was to test the hypothesis that chronic reduction in sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA)2 levels in combination with an increased hemodynamic load will result in an accelerated pathway to heart failure. Age-matched wild-type and Serca2ϩ/Ϫ mice were subjected to 10 wk of pressure overload via transverse aortic coarctation surgery. Cardiac hypertrophy and heart failure were assessed by echocardiography, gravimetry/histology, hemodynamics, and Western blotting analyses. Our results showed that ϳ64% of coarcted Serca2ϩ/Ϫ mice were in heart failure compared with 0% of coarcted wild-type mice (P Ͻ 0.05). Overall, morbidity and mortality were greatly increased in Serca2ϩ/Ϫ mice under pressure overload. Echocardiography assessment revealed a significant increase in left ventricular (LV) mass, and LV hypertrophy in coarcted Serca2ϩ/Ϫ mice converted from a concentric to an eccentric pattern, similar to that seen in human heart failure. Coarcted Serca2ϩ/Ϫ mice had decreased contractile/systolic and relaxation/diastolic performance and/or function compared with coarcted wild-type mice (P Ͻ 0.05), despite a similar duration and degree of pressure overload. SERCA2a protein levels were significantly reduced (Ͼ50%) in coarcted Serca2ϩ/Ϫ mice compared with noncoarcted and coarcted wild-type mice. Our findings suggest that reduction in SERCA2 levels in combination with an increased hemodynamic load results in an accelerated pathway to heart failure. sarco(endo)plasmic reticulum calcium-adenosine 5Ј-triphosphatase pump; knockout mice; echocardiography; cardiac dysfunction SARCO(ENDO)PLASMIC RETICULUM Ca 2ϩ -ATPase (SERCA) in the heart plays a pivotal role in the beat-to-beat function of the heart. The SERCA pump promotes muscle relaxation by lowering the cytosolic Ca 2ϩ concentration and through active Ca 2ϩ transport restores the intracellular Ca 2ϩ stores, thus providing Ca 2ϩ needed for the next contraction. Decreases in SERCA pump expression and activity have been observed in a variety of pathological conditions. In particular, defects in the sarcoplasmic reticulum (SR) Ca 2ϩ uptake function have been identified in animal models of heart disease and have been shown to correlate with altered contractile function. It has been shown that the expression level of SERCA and Ca 2ϩ transport is significantly decreased in pressure overload-induced hypertrophy and during heart failure (1, 9, 18, 23, 28, 31). Studies on human hearts, primarily explant hearts, suggest that SR Ca 2ϩ transport function is altered in end-stage human heart failure (2, 11, 12). A decrease in the level of SERCA (mRNA, protein, or activity) was closely correlated with decreased myocardial function and impaired force-frequency response (1, 3, 12, 24, 30) . These studies suggest that the SERCA pump level is critical for the maintenance of cardiac function, but the true relationship between SERCA levels and cardiac function is difficult to establish. Interpretation of studies using tissues from end-stage failing hearts is difficult because multiple changes occur within myocytes during the progression into heart failure. Therefore, whether decreased SERCA expression and/or activity is a cause or a consequence of heart failure is under debate.
sarco(endo)plasmic reticulum calcium-adenosine 5Ј-triphosphatase pump; knockout mice; echocardiography; cardiac dysfunction SARCO(ENDO)PLASMIC RETICULUM Ca 2ϩ -ATPase (SERCA) in the heart plays a pivotal role in the beat-to-beat function of the heart. The SERCA pump promotes muscle relaxation by lowering the cytosolic Ca 2ϩ concentration and through active Ca 2ϩ transport restores the intracellular Ca 2ϩ stores, thus providing Ca 2ϩ needed for the next contraction. Decreases in SERCA pump expression and activity have been observed in a variety of pathological conditions. In particular, defects in the sarcoplasmic reticulum (SR) Ca 2ϩ uptake function have been identified in animal models of heart disease and have been shown to correlate with altered contractile function. It has been shown that the expression level of SERCA and Ca 2ϩ transport is significantly decreased in pressure overload-induced hypertrophy and during heart failure (1, 9, 18, 23, 28, 31) . Studies on human hearts, primarily explant hearts, suggest that SR Ca 2ϩ transport function is altered in end-stage human heart failure (2, 11, 12) . A decrease in the level of SERCA (mRNA, protein, or activity) was closely correlated with decreased myocardial function and impaired force-frequency response (1, 3, 12, 24, 30) . These studies suggest that the SERCA pump level is critical for the maintenance of cardiac function, but the true relationship between SERCA levels and cardiac function is difficult to establish. Interpretation of studies using tissues from end-stage failing hearts is difficult because multiple changes occur within myocytes during the progression into heart failure. Therefore, whether decreased SERCA expression and/or activity is a cause or a consequence of heart failure is under debate.
To understand how decreased SERCA levels affect cardiac physiology, we generated Serca2 knockout mice with genetargeting techniques (29, 16) . As expected, the disruption of both copies of Serca2 gene resulted in early embryonic lethality, whereas heterozygous mice (Serca2ϩ/Ϫ) with a single functional allele are alive and reproduce well. These mice have provided us with an in vivo model system to study how a decrease in SERCA pump levels affects the contraction-relaxation cycle of the heart. Serca2ϩ/Ϫ mice showed decreased SERCA2a protein levels as well as a lower maximal velocity of SR Ca 2ϩ uptake, both reduced by ϳ35% (16, 29) . Analyses of in vivo cardiac function with a Millar catheter revealed decreased maximal rates of contraction and relaxation and lower mean arterial pressure in Serca2ϩ/Ϫ mice. Interestingly, the heart weight-to-body weight ratio was normal in Serca2ϩ/Ϫ mice. The hearts of Serca2ϩ/Ϫ mice did not show any signs of cardiac hypertrophy or fibrosis as analyzed by light microscopy. Despite a reduction in SERCA pump levels, there was no evidence of cardiac pathology in Serca2ϩ/Ϫ mice. We therefore reasoned that Serca2ϩ/Ϫ hearts were able to meet the functional requirements under normal conditions. However, it was not known whether Serca2ϩ/Ϫ hearts would be able to adapt well to a pathological stress such as increased hemody-namic load. In the present study, we tested the hypothesis that chronic reduction in SERCA2 levels in combination with an increased hemodynamic load will result in an accelerated pathway to heart failure. Our results show that heart failure occurs more rapidly with reduced SERCA2 levels in conjunction with pressure overload.
MATERIALS AND METHODS
Mice were housed in a specific pathogen-free facility and handled in accordance with standard use protocols and animal welfare regulations. The generation of Serca2ϩ/Ϫ mice was described previously (29) . All protocols were approved by the University of Cincinnati Institutional Animal Care and Use Committee.
Wild-type and Serca2ϩ/Ϫ mice (10-12 wk of age) were randomly assigned to the present study, and 11 wild-type and 11 Serca2ϩ/Ϫ mice subjected to aortic coarctation (AC) completed the study, which included echocardiography, blood pressure and left ventricular (LV) measurements, gravimetry/histology, and SERCA2a and calsequestrin (Csq) protein determination. After AC, four Serca2ϩ/Ϫ mice died because of heart failure. No mortality was observed in wild-type mice committed to the 10-wk study.
AC surgery. Age-matched wild-type and Serca2ϩ/Ϫ mice of either sex weighing 22-26 g were anesthetized intraperitoneally with 2.5% Avertin (0.017 ml/g). A tracheotomy was performed, and the mouse was artificially ventilated with room air (120 breaths/min with a tidal volume of 0.3 ml) with a Harvard Apparatus mouse ventilator (model 687; South Natick, MA). AC surgery was performed as described previously (35) , and the surgeon was blinded to the identity of the mice. In brief, a blunt dissection was performed at the second intercostal space to expose the aortic arch. A 7-0 silk suture was placed around the aorta between the left common carotid artery and brachiocephalic trunk. A 27-gauge needle, bent to an L shape, was placed on top of the exposed transverse aorta. Tying the suture around this needle and subsequent removal of the needle produced banding of the aorta. The lungs were reexpanded with positive pressure, and the chest and skin incisions were closed with 5-0 silk and 5-0 Ti-cron, respectively. The trachea incision was closed with 7-0 silk. The mice were monitored daily for 10 wk.
Echocardiography. Echocardiography was performed preoperatively and once a week postoperatively for 10 wk on wild-type and Serca2ϩ/Ϫ mice as previously described (35) . Intra-and interobserver variability was similar to that previously noted in our laboratory (36) , and the sonographers were blinded to the identity of the mice. Two-dimensional and M-mode measurements of LV end-diastolic and end-systolic chamber size, septal wall thickness and LV posterior wall thickness (PWT) in diastole and systole, and R-R interval were made from original tracings, as recommended by the American Society of Echocardiography (33) . LV mass was estimated with the cube formula, and cardiac function (fractional shortening, FS) was calculated (35) . Changes in diastolic function were assessed by calculating the peak E-to-A ratio and isovolumic relaxation time (IVRT). Peak E (rapid ventricular filling) velocity and peak A (filling during atrial contraction) velocity through the mitral valve were measured from the apical four-chamber view at the tips of the mitral leaflets. Peak E/A is an indicator of LV filling. IVRT was obtained from continuous-wave Doppler of the LV outflow and inflow tracts. IVRT is the time interval from aortic valve closure to mitral valve opening and is a measure of LV relaxation as related to left atrial pressure.
In vivo hemodynamic measurements. Blood pressure measurements and cardiac function were obtained with a Millar catheter as described previously (34, 35) . After echocardiographic assessment, age-and sex-matched noncoarcted (NC) and 10-wk AC wild-type and Serca2ϩ/Ϫ mice were surgically instrumented as described previously (21) . Average values for heart rate, mean arterial blood pressure, systolic blood pressure, and left intraventricular pressure (LVP) were measured directly from the pressure waveforms. Maximum and minimum change in pressure over time (dP/dt) were derived from a Fig. 1 . Tissue weight-to-body-weight (BW) ratios for age-and sex-matched noncoarcted (NC) and 10-wk aortic coarctation (AC) wild-type and Serca2ϩ/Ϫ mice. Mice were subjected to sham surgery or AC for 10 wk to induce a chronic pressure overload. Tissues were harvested to identify mice that underwent cardiac hypertrophy and/or had signs of pulmonary edema, an indication of heart failure. Values are expressed as means Ϯ SE; n ϭ 4 for NC wild-type mice, 4 for NC Serca2ϩ/Ϫ mice, 11 for AC wild-type mice, and 7 for AC Serca2ϩ/Ϫ mice. Four AC Serca2ϩ/Ϫ mice died during the course of the study and were not included in the tissue weight analysis. LV, left ventricle. differential tracing of LVP. At the end of the experimental protocol, mice were killed, organs including the heart, lungs, kidney, and colon were harvested, and the tissue was weighed and normalized to mouse body weight and tibia length. The tissue was either placed in liquid nitrogen and stored at Ϫ80°C for Western blot analysis or placed in 4% paraformaldehyde for histological determination.
Western blot analysis. To determine the protein levels, hearts from AC and NC animals were homogenized in 10 mM imidazole (pH 7.0), 0.3 M sucrose, 0.3 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, and 10 mM sodium fluoride. Protein concentration was determined by the Bradford method with bovine serum albumin for the standard curve. The homogenates were electrophoretically separated on a 10% SDS polyacrylamide gel, blotted onto a 0.22-m nitrocellulose membrane, and probed with polyclonal antibody raised against SERCA2a (16) . In addition, antibodies specific for phospholamban (PLB) and Csq were used to probe the Western blots (polyclonal PLB and anti-Csq antibodies were from Affinity BioReagents, Golden, CO). Csq was used to correct loading variations between samples because it did not vary significantly between control and banded samples. The signal obtained for each sample was quantified by densitometry with a UMAX Astra 1200s scanner and NIH Image software (version 1.62) (16) .
Statistical analysis of data. All values are expressed as means Ϯ SE. Tissue weight-to-body weight ratios, in vivo hemodynamic measurements, and SERCA2a and Csq protein levels were compared by one-way ANOVA with Fisher's least-significant difference post hoc test. Differences between echocardiographic data were compared with two-way ANOVA for time and treatment with repeated measures with Fisher's least-significant difference test. Statistical differences were considered significant at P Ͻ 0.05.
RESULTS
Gravimetric analysis reveals a heart failure phenotype in Serca2ϩ/Ϫ mice after 10 wk of pressure overload. Wild-type and Serca2ϩ/Ϫ mice were subjected to 10 wk of pressure overload via transverse AC surgery. Echocardiography was performed at 1-week intervals to follow the development and progression of cardiac hypertrophy and heart failure. Gravimetric, histological, hemodynamic, and molecular measurements were also obtained for age-and sex-matched NC and 10-wk AC wild-type and Serca2ϩ/Ϫ mice.
Gravimetric analysis showed that both 10-wk AC wild-type and Serca2ϩ/Ϫ mice had a significant increase in whole heart weight-and LV weight-to-body weight ratio compared with NC cohorts (P Ͻ 0.05; Fig. 1 ). Interestingly, there was a Values are means Ϯ SE. LVED, left ventricular end-diastolic chamber size (mm); LVES, left ventricular end-systolic chamber size (mm); SWT, septal wall thickness at end diastole (mm); PWT, posterior wall thickness at end diastole (mm); HR, heart rate (beats/min); SV, stroke volume (ml); CO, cardiac output (ml/min); AC, aortic coarctation. *P Ͻ 0.05 vs. prebanded cohort; †P Ͻ 0.05 vs. wild-type 10-wk AC. further significant increase in whole heart weight-and LV weight-to-body weight ratio in AC Serca2ϩ/Ϫ mice compared with AC wild-type mice (P Ͻ 0.05; Fig. 1 ). Heart weights were not significantly different between NC wild-type and Serca2ϩ/Ϫ mice, whereas AC animals had a significant increase in heart weight (NC wild type ϭ 128 Ϯ 11 mg; NC Serca2ϩ/Ϫ ϭ 127 Ϯ 13 mg; AC wild type ϭ 152 Ϯ 10 mg; AC nonfailing Serca2ϩ/Ϫ ϭ 160 Ϯ 14 mg; AC failing Serca2ϩ/Ϫ ϭ 159 Ϯ 9 mg). Body weights were not different between NC and AC wild-type and Serca2ϩ/Ϫ mice (NC wild type ϭ 31 Ϯ 3 g; NC Serca2ϩ/Ϫ ϭ 30 Ϯ 4 g; AC wild type ϭ 30 Ϯ 2 g; AC nonfailing Serca2ϩ/Ϫ ϭ 27 Ϯ 2 g; AC failing Serca2ϩ/Ϫ ϭ 24 Ϯ 4 g), indicating that the increase in whole heart weight-and LV weight-to-body weight ratio in AC Serca2ϩ/Ϫ mice was not the result of diminished murine body weight. Wet lung weight-to-body weight ratio, an experimental measure of pulmonary edema, revealed a heart failure phenotype in AC Serca2ϩ/Ϫ mice (P Ͻ 0.05; Fig. 1 ). The heart failure phenotype was determined retrospectively and was based on the criterion of wet lung weight-to-body weight ratio (NC wild type range 5.4-7.1; NC Serca2ϩ/Ϫ range 5.6-6.9; 10-wk AC wild type range 4.0-6.3; 10-wk AC Serca2ϩ/Ϫ range 5.1-17.7). In fact, the incidence of heart failure was genotype dependent, as 64% of AC Serca2ϩ/Ϫ mice had pulmonary edema (i.e., significant increase in wet lung weightto-body weight ratio) compared with 0% of AC wild-type mice (P Ͻ 0.05; Fig. 2 ). Dry lung weight-to-body weight ratio was not significantly different in NC and AC wild-type and Serca2ϩ/Ϫ mice, confirming that the excess wet lung weight was due to edema (data not shown). No mortality occurred in 10-wk AC wild-type mice; however, four AC Serca2ϩ/Ϫ mice died between 4 and 8 weeks of pressure overload (i.e., 1 mortality at 4 wk of AC, 2 mortalities at 6 wk of AC, and 1 mortality at 8 wk of AC). Histological assessment of 10-week NC and AC wild-type and Serca2ϩ/Ϫ hearts indicated that AC wild-type hearts had mild myocyte hypertrophy with mild perivascular fibrosis whereas AC Serca2ϩ/Ϫ hearts had diffuse, moderate myocyte hypertrophy and moderate multifocal fibrosis (data not shown).
Echocardiographic assessment demonstrates LV hypertrophy and systolic and diastolic dysfunction in Serca2ϩ/Ϫ mice after pressure overload. Echocardiography showed that AC wild-type and nonfailing Serca2ϩ/Ϫ mice had similar increases in LV mass; however, the increase in LV mass was significantly greater for failing Serca2ϩ/Ϫ mice compared with AC wild-type mice at 5 and 10 wk of AC (P Ͻ 0.05; Fig.  3 ). There were no differences in LV mass between wild-type and Serca2ϩ/Ϫ mice before AC. No significant LV chamber dilation occurred in AC wild-type and nonfailing Serca2ϩ/Ϫ mice (Table 1) . However, there was a significant increase in LV chamber dilation and PWT in AC failing Serca2ϩ/Ϫ mice (P Ͻ 0.05; Table 1) , demonstrating an eccentric, dilated form of hypertrophy. A significant increase in PWT in AC wild-type and nonfailing Serca2ϩ/Ϫ mice was also observed (P Ͻ 0.05; Table 1 ), indicating a concentric form of hypertrophy in these mice.
Cardiac function assessed by echocardiography demonstrated that AC Serca2ϩ/Ϫ mice had significant systolic (measured as FS) and diastolic (measured as IVRT and E/A) dysfunction compared with AC wild-type mice (P Ͻ 0.05; Figs. 4 and 5 ). There was a 51% reduction in FS in 10-wk AC failing Serca2ϩ/Ϫ mice compared with AC wild-type and nonfailing Serca2ϩ/Ϫ mice (Fig. 4A) . Serca2ϩ/Ϫ mice had a slower IVRT before AC compared with wild-type mice (P Ͻ 0.05; Fig. 4B ), which supports our earlier findings (29) of a slower rate of relaxation in Serca2ϩ/Ϫ mice. After AC, IVRT was further elevated in Serca2ϩ/Ϫ mice, indicating severe diastolic dysfunction (Fig. 4B) . Another measure of diastolic function is E/A, which is a measure of ventricular filling, both passive (E) and via atrial contraction (A), and is influenced by the speed of LV relaxation and LV compliance. Before AC, Serca2ϩ/Ϫ mice had an elevated E/A compared with wild-type mice (P Ͻ 0.05; Fig. 5B ). After 10 wk of AC, failing Serca2ϩ/Ϫ mice had a significant increase in E/A compared with 10-wk AC wild-type mice and prebanded Serca2ϩ/Ϫ mice (P Ͻ 0.05; Fig. 5B ). Although not significant, there was also an elevation of E/A of nonfailing Serca2ϩ/Ϫ mice after AC compared with wild-type mice and prebanded Serca2ϩ/Ϫ mice. Different E/A patterns of diastolic filling were observed in coarcted Serca2ϩ/Ϫ mice (Fig. 5A) . The images depicted in There was no difference in the heart rate or pressure gradient produced in wild-type and Serca2ϩ/Ϫ mice to account for the cardiac hypertrophy and/or remodeling and functional differences observed (see Tables 1 and 2 ). The echocardiographic measurements of pressure gradient after AC are comparable to the gradients obtained from catheterizations of the LV and femoral artery as shown previously (35) .
LV catheterization study reveals systolic and diastolic dysfunction in Serca2ϩ/Ϫ mice after pressure overload. As previously observed (29) , LV catheterization demonstrated that age-and sex-matched NC Serca2ϩ/Ϫ mice had a significant decrease in ϩdP/dt and ϪdP/dt compared with NC wild-type mice (P Ͻ 0.05; Fig. 6 ). Consistent with the functional assessment obtained by echocardiography, a subpopulation of 10-wk AC Serca2ϩ/Ϫ mice had significant systolic and diastolic cardiac dysfunction, as measured by the rates of contraction and relaxation (ϩdP/dt and ϪdP/dt, respectively), compared with AC wild-type mice (P Ͻ 0.05; Fig. 6 ), despite a similar duration and degree of pressure overload (Table 2 ). In addition, peak LV systolic pressure, as measured by the Millar catheter Fig. 6 . LV catheterization assessment of contractile (ϩdP/dt; A) and relaxation (ϪdP/dt; B) performance in NC and 10-wk AC wild-type and Serca2ϩ/Ϫ mice. Hemodynamic measurements were obtained in closed-chest mice. A fluid-filled catheter was placed in the femoral artery for systemic blood pressure measurements, and a Millar catheter was placed in the LV for intraventricular pressure measurements. Values are expressed as means Ϯ SE; n ϭ 4 for NC wild-type mice, 4 for NC Serca2ϩ/Ϫ mice, 11 for AC wild-type mice, and 7 for AC Serca2ϩ/Ϫ mice. WT, wild type; ϩ/Ϫ, Serca2ϩ/Ϫ; NF, nonfailing; F, failing. placed proximal to the aortic coarctation, was not different between Serca2ϩ/Ϫ mice and wild-type mice after 10 wk of AC (Table 2) , confirming matched hemodynamic loads. Both AC wild-type and nonfailing Serca2ϩ/Ϫ mice had enhanced rates of contraction and relaxation, suggesting that these mice were in a compensatory stage during pressure overload. LV end-diastolic pressure was significantly elevated in AC failing Serca2ϩ/Ϫ mice compared with AC wild-type mice (6.2 Ϯ 1.7 mmHg in AC failing Serca2ϩ/Ϫ vs. 2.1 Ϯ 0.9 mmHg in AC wild type; P Ͻ 0.05).
Pressure overload results in a further decrease in SERCA2 protein levels in Serca2ϩ/Ϫ mice. Western blot analysis revealed that 10-wk AC wild-type mice had a 14% reduction in SERCA2a protein levels compared with their NC cohorts (P Ͻ 0.05; Fig. 7B ). AC Serca2ϩ/Ϫ mice had a further 36% reduction in SERCA2a protein levels (for a total reduction of 56% compared with NC wild-type mice) compared with their NC cohorts, which started with an initial 20% reduction in SERCA2a protein levels (P Ͻ 0.05; Fig. 7B ). Compared with AC wild-type mice, SERCA levels were significantly decreased in Serca2ϩ/Ϫ mice after 10 wk of pressure overload. On the other hand, Csq protein levels were not significantly different between NC and AC cohorts. Our analysis of PLB expression showed that PLB was not significantly different between AC and NC samples in wild-type and Serca2ϩ/Ϫ mice (data not shown). These data suggest that the severity of heart failure may relate to the greater decrease in SERCA levels observed in the AC Serca2ϩ/Ϫ mice.
DISCUSSION
A number of animal models of cardiac hypertrophy and human heart failure have decreased levels of SERCA2 mRNA and/or protein (2, 5, 6, 9, 20, 24) . However, the question remained as to whether there was a causal relationship between decreased levels of SERCA2 and heart failure. We reported previously (16, 29) that disruption of a single copy of the SERCA2 gene (Serca2ϩ/Ϫ mice) results in decreased SERCA2 protein and activity and causes an impairment of basal cardiac performance and altered Ca 2ϩ homeostasis, with no overt signs of cardiac disease.
Our present study has demonstrated that heart failure occurs more rapidly and more frequently in mice with chronically reduced SERCA2 levels in conjunction with a pathological stress (i.e., increased hemodynamic load). Systolic and diastolic performance is significantly decreased in 10-wk AC Serca2ϩ/Ϫ mice. Also, these mice (Serca2ϩ/Ϫ) had a significant degree of cardiac hypertrophy and dilatation compared with wild-type mice after pressure overload, which suggests that Ca 2ϩ handling via the SERCA2 pump may not only regulate cardiac function but also influence cardiac remodeling during disease events. The functional and remodeling parameters were significantly different between AC wild-type and Serca2ϩ/Ϫ mice despite a similar duration and degree of pressure overload. Western blot analysis revealed that Serca2ϩ/Ϫ mice subjected to pressure overload had a further reduction in SERCA2, which may account for the systolic and diastolic dysfunction observed in AC Serca2ϩ/Ϫ mice (see Fig. 7 ). These data suggest that depressed levels of SERCA2 protein and its activity below a certain threshold (e.g., Ͼ35% reduction in SERCA2 protein and activity) contribute to the onset and progression of heart failure. Our findings correlate well with recent studies showing that a defect in SR Ca 2ϩ uptake function can contribute to cardiac dysfunction and pathology. Dash et al. (4) showed that fourfold overexpression of PLB (inhibitor of SERCA) in transgenic mice resulted in depressed Ca 2ϩ transport (as evidenced by prolonged Ca 2ϩ transients) and mechanical function. Young transgenic animals showed no signs of heart failure and maintained a full response to isoproterenol in vivo. However, on aging (15-18 mo), transgenic mice exhibited a progression to cardiac hypertrophy, LV chamber dilatation, and heart failure and sudden death (4). In addition, treatment of mice with ryanodine, an inhibitor of the SR Ca 2ϩ release channel, resulted in cardiac hypertrophy and contractile dysfunction, suggesting that defects in SR Ca 2ϩ handling can cause cardiac pathology (25) . Although we have suggested that the level of SERCA2 protein and/or activity may impact the heart's ability to handle chronically increased pressure load, ultimately leading to heart failure, modifying other signaling mechanisms involved in cardiac remodeling and/or contractility could exhibit profound effects on the maintenance of cardiac function in response to hemodynamic overload. For example, mitogen-activated protein kinase and ERK kinase kinase 1 knockout mice were shown to be susceptible to pressure overload and to developing cardiac dysfunction compared with control wild-type mice, although it is not known whether SERCA2 levels were decreased in this model as they were not studied (32) . However, a study by Kiriazis and colleagues (17) demonstrated that SERCA2 protein levels were markedly decreased (50%) in coarcted failing wild-type and PLB knockout mice, whereas coarcted nonfailing wild-type mice had a 24% reduction in SERCA2 protein, and these levels of SERCA2 protein correlated with FS. Our data are consistent with those of Kiriazis et al. (17) in that we detected a 56% reduction in SERCA2 protein levels in AC failing Serca2ϩ/Ϫ mice and AC nonfailing wild-type mice had only a 14% reduction in SERCA2 (see Fig. 7 ).
Targeted expression of the SERCA pump in transgenic mouse hearts has been shown to improve cardiac function, increase systolic Ca 2ϩ transients, and accelerate relaxation rate (13, 22, 19) . In addition, studies have examined the benefit of increased SERCA pump levels during pressure overload-induced cardiac hypertrophy in genetically altered animal models. Ito et al. (15) found decreased mortality in 7-wk banded transgenic SERCA2a mice vs. banded controls showed and that transgenic animals maintained increased SERCA levels and enhanced contractile function even after banding. However, the magnitude of hypertrophy was similar in both controls and transgenic mice (15) . These studies conclude that enhanced SERCA levels maintain increased SR Ca 2ϩ load and contractile function, which therefore modify the outcome of pressure overload-induced remodeling.
In general, genetic manipulations that improve Ca 2ϩ transport either by SERCA gene therapy or PLB ablation have been shown to be beneficial and to prevent cardiac dysfunction and ventricular remodeling in both transgenic and surgically induced heart failure models (7, 8, 10, 14, 26, 27 ). Recently, it was shown that ablation of PLB could prevent heart failure in a mouse model of dilated cardiomyopathy caused by deficiency in a cytoskeletal protein the muscle-specific Lim protein (26) . Further PLB ablation prevented systolic dysfunction and exercise intolerance, but not hypertrophy (10) , in a hypertrophic cardiomyopathy mouse model resulting from Arg403Gln mutation in myosin heavy chain. Hoshijima et al. (14) showed that sustained expression of pseudophosphorylated PLB into Bio 14.6 cardiomyopathic hamsters improves Ca 2ϩ transport and contractile function. Adenoviral gene transfer studies by Hajjar and colleagues (7, 8, 27) showed that SERCA2a gene transfer can improve survival, ventricular function, and energy metabolism in an experimentally induced heart failure model. These studies clearly point out that restoration of normal Ca 2ϩ transport can be beneficial; it can prevent ventricular dysfunction as well as cardiac remodeling triggered by a defect in Ca 2ϩ transport.
In conclusion, our findings suggest that a decrease in SERCA pump level can lead to cardiac dysfunction and heart failure when the heart is subjected to an increase in physiological demands. This study presents evidence that hearts with decreased SERCA levels are at greater risk and develop heart failure, thus suggesting that a decrease in SERCA levels may contribute to worsening function, thus leading to failure.
